Interestingly, a new preclinical study showed that treatment with lipid-protamine-DNA nanoparticles loaded with genes against IL-10 and CXCL12 significantly reduced tumor growth by changing the TME landscape with lower immunosuppressive cells (M2+ macrophages, MDSCs), and activated tolerogenic DC and NK cells [145]. This evidence concerns the gene CXCL12 and neoplasm.